Anne Wojcicki
Anne Wojcicki is the co-founder and former CEO of 23andMe, a personal genomics and biotechnology company she co-founded in 2006. She has been instrumental in making genetic testing accessible to the public, empowering individuals with information about their ancestry and health predispositions. Under her leadership, 23andMe became the first company to receive FDA approval for a direct-to-consumer cancer-risk genetic test. Anne Wojcicki co-founded 23andMe in 2006, aiming to make genetic information accessible to individuals. In 2008, Time magazine recognized 23andMe's retail saliva genetic test as "Invention of the Year." She successfully navigated regulatory challenges, leading 23andMe to become the first company to receive FDA approval for direct-to-consumer genetic health risk reports in 2015. Wojcicki was named one of TIME's "Most Influential People" in 2009 and Forbes' "Global Gamechangers" in 2017. Under her leadership, 23andMe went public in 2021. These milestones underscore her commitment to empowering individuals with genetic insights for proactive health management and advancing personalized medicine.
Career Milestones
- Co-founded 23andMe in 2006 to make genetic information accessible to individuals.
- In 2008, Time magazine recognized 23andMe's retail saliva genetic test as "Invention of the Year."
- In 2015, led 23andMe to become the first company to receive FDA approval for direct-to-consumer genetic health risk reports.
- Named one of TIME's "Most Influential People" in 2009 and Forbes' "Global Gamechangers" in 2017.
- Under her leadership, 23andMe went public in 2021, marking a major milestone in consumer genomics.
About 23andMe
23andMe, founded in 2006, is a personal genomics and biotechnology company. They help individuals understand their DNA for ancestry, health predispositions, and traits. Their target audience is typically health-conscious individuals aged 35-65. Core features include DNA testing kits, personalized genetic reports, and tools for family tree building. Benefits include insights into health risks, ancestry, and carrier status.